REPLIGEN CORP (RGEN) Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Medical - Instruments & Supplies
Repligen Corporation NASDAQ:RGEN Healthcare · Medical - Instruments & Supplies
Mkt Cap $11.31B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 2
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
Repligen priced $1.0 billion of 0.25% Convertible Senior Notes due 2031, with roughly $541.4 million exchanged against $456.8 million of its 1.00% 2028 notes and about $458.6 million issued for cash.
The initial conversion price of approximately $226.37 represents a 20% premium to the October 29 close, and only $143.2 million of the 2028 notes will remain outstanding after the November 6 expected close.
CFO Jason Garland said the deal extends debt duration, reduces interest expense, and is expected to be nominally accretive to adjusted EPS in 2026. Repligen is also repurchasing $120.0 million of stock at $188.64 per share to facilitate the transactions, with remaining proceeds earmarked for working capital and potential M&A.
• 2d ago AI analysis › Press Release ● Major ⚠ 2
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen reported record Q3 2026 revenue of $209.3 million, up 11% as reported and 12.5% organically, with adjusted EPS of $0.53 versus $0.46 a year ago.
The company closed its acquisition of BioLife Solutions on October 6, adding a recurring-revenue cell-therapy consumables platform, and opened a new Training & Innovation Center in Seoul.
Full-year 2026 guidance was raised to $844M-$852M in revenue (14.5%-15.5% reported growth) with adjusted diluted EPS of $2.05-$2.09.
On a GAAP basis Repligen posted a Q3 operating loss of $29.5 million and diluted loss per share of $0.68, driven by a $41.2 million non-cash intangible impairment charge.
• 5d ago AI analysis › Press Release
Repligen to Report Third Quarter 2026 Financial Results
Repligen announced it will report third quarter 2026 financial results on Tuesday, October 27, 2026, before the market opens.
The company will host a conference call the same day at 8:00 a.m. ET to discuss business updates and results for the quarter ended September 30, 2026, with a webcast available via its investor relations website.
This is a routine scheduling notice containing no financial results or operational news.
• 19d ago AI analysis › Press Release ● Major
Repligen Completes Acquisition of BioLife Solutions
Repligen has completed its acquisition of BioLife Solutions, making BioLife shareholders recipients of $11.25 per share in cash plus 0.1442 Repligen shares per share.
BioLife brings a high-margin, recurring-revenue biopreservation media business led by CryoStor, which supports 18 commercially approved cell and gene therapies.
Repligen will detail the deal's expected impact on its 2026 financial outlook on its upcoming Q3 2026 earnings call; BioLife will now be absorbed into the combined commercial platform.
• 26d ago AI analysis › Press Release
Freshworks Set to Join S&P SmallCap 600
S&P Dow Jones Indices announced BioLife Solutions will be removed from the S&P SmallCap 600 effective prior to the open on October 8, 2026.
The deletion stems from Repligen's pending acquisition of BioLife Solutions, which is expected to be completed soon pending final closing conditions.
Freshworks will replace BioLife in the index. For BLFS holders, the primary driver is the imminent deal close rather than the mechanical index removal.
• 27d ago AI analysis › Press Release
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
Repligen Corporation announced that its executive management team will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston.
President and CEO Olivier Loeillot and CFO Jason Garland are scheduled to take part in an analyst-led discussion on September 9 at 1:30 p.m. ET.
Investors can access a live webcast of the presentation via the company’s investor relations website, with replay available afterwards.
• 2mo ago AI analysis › Press Release ● Major ⚠ 1
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen reported Q2 revenue of $204 million, representing a 12% year-over-year increase on a reported basis and 13% organic growth, alongside a 55% jump in adjusted operating income to $34 million.
Based on the strong first half performance, management raised full-year 2026 guidance, increasing organic growth expectations to 10.5%-13.5% and adjusted EPS to $2.03-$2.09.
The company also announced a definitive agreement to acquire BioLife Solutions, a move intended to accelerate its cell therapy leadership and drive accretive revenue growth.
• 3mo ago AI analysis › Press Release ● Critical
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
BioLife Solutions (BLFS) has agreed to be acquired by Repligen (RGEN) for $31.00 per share in a transaction valued at approximately $1.5 billion.
BioLife stockholders will receive $11.25 in cash and 0.1442 shares of RGEN common stock for each share held, representing a 24% premium to the 90-day volume-weighted average price.
The transaction is expected to close in the fourth quarter of 2026, subject to regulatory and stockholder approvals, and is projected to generate at least $20 million in synergies in year one.
• 3mo ago AI analysis › Press Release
Repligen to Report Second Quarter 2026 Financial Results
Repligen Corporation announced that it will report its second quarter 2026 financial results on Tuesday, July 28, 2026, prior to the market open.
The company plans to host a conference call at 8:00 a.m. ET on the same day to discuss business updates and financial results for the three-month period ended June 30, 2026.
• 3mo ago AI analysis › Press Release
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen Corporation will participate in the William Blair 46th Annual Growth Stock Conference in Chicago.
CEO Olivier Loeillot is scheduled to present a company overview on June 3 at 10:40 a.m. CT.
A live webcast of the presentation will be available on Repligen’s Investor Relations website.
• 5mo ago AI analysis › Press Release
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
Repligen published its 2025 Corporate Sustainability Report, highlighting progress across six key impact areas including operations, talent, and supply chain.
The report notes that the company maintained 100% renewable electricity across its U.S. and European manufacturing operations and decreased global water withdrawals by 14% year-over-year.
Repligen also completed its first enterprise-level Double Materiality Assessment aligned with European Sustainability Reporting Standards (ESRS) and expanded Board sustainability oversight to the Audit Committee.
• 5mo ago AI analysis › Press Release
Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
Repligen Corporation announced that CFO Jason Garland will present at the Bank of America Securities 2026 Global Healthcare Conference in Las Vegas on May 12.
The presentation will be webcast live on the company's investor relations website and available for replay afterward.
Repligen is a global life sciences company focused on bioprocessing technologies for biological drug manufacturing.
• 5mo ago AI analysis › Press Release ● Major
Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen reported Q1 2026 revenue of $194 million, up 15% year-over-year as reported (11% organic), with adjusted EPS increasing 23% to $0.48.
The company exceeded expectations for the quarter, driven by 160 basis points of adjusted operating margin expansion, and raised its full-year adjusted EPS guidance to $1.97-$2.05.
Strategic highlights include the divestiture of the non-core Polymem business and a new OEM partnership in China to support APAC growth.
• 5mo ago AI analysis › Press Release
Repligen to Report First Quarter 2026 Financial Results
Repligen Corporation announced it will report its first quarter 2026 financial results on Tuesday, May 5, 2026.
The company will issue a press release before the market opens and host a conference call at 8:00 a.m. ET to discuss business updates and results for the period ended March 31, 2026.
Investors can access the live call via webcast or telephone, with a replay available subsequently.
• 6mo ago AI analysis › Press Release
Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
globenewswire.com • 6mo ago 
